Abstract: Intermittent Recombinant Human Parathyroid Hormone (rhPTH 1-34) is an effective treatment for improving bone mass in patients with osteoporosis; however, its effects on bone regeneration are still unclear. The objective of this study was to evaluate the potential toxicity systemic rhPTH, as well as its ability to regenerate critical-sized defects (CZD) in bone. We used 43 female Wistar rats (body weight, 150 ± 50 g). Critical-sized bone defects in rat calvaria received vehicle alone (Control Group, CG) or daily rhPTH (20 g/ Kg/day) by subcutaneous injection (Experimental Group, EG). We evaluated bone healing obtained at the 1st, 3rd, and 6th wks post-surgery by biochemical, soft x-ray, histological, and morphometric studies. In the EG, at the 1st and 3rd wks, many areas of focal osteoblast hyperplasia were found on parietal bone. At the 3rd wk, woven and/or lamellar bone, in an organized interconnected trabecular network, showed disrupted mineralization. At the 6th wk, looped bone was found to have formed patterns on parietal bone. New bone formed in the EG showed significant statistical differences (p = 0.023) at the 6th wk. Systemic rhPTH at the dose of 20 g/Kg/ day was able to stimulate bone formation on rat CZD. Also, pre-existing and new bone showed non-proliferative forms of bone hyperostosis (increased non-neoplastic bone).
Introduction
Endogenous Parathyroid Hormone (PTH 1-84) plays a key role in calcium homeostasis and bone metabolism 1) . A continuous measure of exogenous PTH increases bone resorption, whereas its periodic administration stimulates new bone formation 2) .
Increased osteoblast numbers have been shown in adult rats after daily PTH administration, by the proliferation of osteoprogenitors from lining cell differentiation 3) . Moreover, PTH stimulates osteoprogenitor cell proliferation and differentiation from bone marrow. PTH binds osteoblast and osteocyte receptors and influences increased expression of early genes (c-fos, c-myc, cjun, and IL-6) involved in cell proliferation 4) . Also, in vitro, PTH showed a mitogenic effect mediated by transforming growth factor (TGF ) 5) . Moreover, improved insulin growth factor-I synthesis and secretion from osteoblast-like cells have been demonstrated 6) .
In 2002, recombinant human parathyroid hormone (rhPTH was approved by the US Food and Drug Administration (FDA) for osteoporosis treatment. It has the same N-terminal amino acid sequence-biologically active region-as full-length Human Parathyroid Hormone 7) . It is assumed that the biological activity of intact PTH (hPTH 1-84) resides in the N-terminal sequence; many studies have used the 34-amino-acid peptide hPTH(1-34), now named "Teriparatide". In contrast, Hodsman et al. 8) reported that it is conceivable that whole PTH may have slightly different biological actions compared with those of Teriparatide. The aim of this study was to determine the capacity of rhPTH, administered systemically, to regenerate critical-sized defects in bone. Of the limited research available, none addresses the action of Teriparatide. In this regard, Nozaka et al. 9) used PTH 1-34 in osteoporotic animals with non-critical-sized bone defects, and demonstrated enhanced bone repair in tibial osteotomies. Komatsu et al. 10) had similar results in femoral circular defects. Bone unable to heal spontaneously 11, 12, 13, 14) treated subcutaneously with intermittent PTH (1-34), combined with osteoconductive replacement material, polytetrafluoroethylene, and tricalcium phosphate scaffolds, respectively, showed enhanced mechanical strength and increased bone deposition. However, the systemic administration of rhPTH without matrices for the treatment of critical-sized defects remains to be elucidated. In this regard, whether rhPTH induces de novo bone formation has not been demonstrated. Therefore, we hypothesized that the intermittent systemic administration of rhPTH, 20 g/Kg/day, induced bone formation on CZD to repair large bone defects. 
Materials and Methods Animals

Experimental design
The research protocol was submitted to and approved by the local Ethical Committee for Animal Research (Tucumán National University & CONICET). Critical-sized defects were created in calvariae as previously described 11, 12) . Briefly, defects were created manually with the use of a 5-mm-diameter ad hoc punch with smooth edges. Animals were randomly assigned to one of two groups: (A) The Control Group (CG-18n) received only vehicle (saline solution), and (B) the Experimental Group (EG-25n) was treated with 20 g/kg/day of rhPTH (Forteo-Teriparatida, Eli Lilly) via subcutaneous injection. The dose used in this study was based on Vahle et al. 15) who demonstrated that rhPTH 5-30 g/kg/day was able to induce bone formation without side-effects. After 1, 3, or 6 wks post-surgery, animals were killed, and bone samples were obtained, fixed in 20% buffered formalin phosphate for 24 hrs, and stored in 70% alcohol prior to analysis.
Assays for serum concentration of rhPTH and bone metabolic markers
At 10 min, 60 min, and 24 hrs after subcutaneous rhPTH injection, blood samples were collected from six animals and placed in ethylenediaminetetraacetic acid (EDTA) tubes, to determine the rhPTH plasma levels by human electrochemiluminescence immunoassay. From all animals, blood samples were obtained by tail bleeding and analyzed for total alkaline phosphatase (ALP), tartrate-resistant acid phosphatase (TRAP), and serum calcium. Urine samples were collected by metabolic cages through 24 hrs for identification of calcium levels.
Soft X-ray by high-resolution films
All samples were subjected to soft x-rays with high-resolution Kodak film (mammography type, 18 x 23 cm; GBA Mamograf HF Digital brand equipment, Buenos Aires, Argentina). Exposure time was 0.8 sec, at 27.5 kV and 7.0 mA 16) .
Histopathology
The specimens were decalcified with modified Morse solution . The criteria used to classify proliferative changes in bones were based on those used in the Teriparatide study 15, 18) .
Histometric studies
Photomicrographs were taken from slides from each specimen by means of a Sony digital camera adapted to an Olympus CH30 
Statistical analysis
Data are presented as mean ± standard deviation, as indicated in the Figs. Biochemistry and histomorphometry results were evaluated by the Mann-Whitney test (p < 0.05).
Bone metabolic markers
The variations from bone metabolic markers are summarized in Figs. 1B-1D. Alkaline phosphatase (ALP) at the 1st wk showed a minimal increase of 146 U/L in the EG, compared with 127 U/L in the CG. This increasing trend continued in treated rats, reaching 1.7 times and 2.9 times at 3 and 6 wks, respectively, in contrast to control group values. Tartrate-resistant acid phosphatase (TRAP) values showed a further 2.5x reduction, in contrast to CG values, in the 1st wk, although, at the 3rd wk, there was a 4x increase compared with CG values, and a decrease at the 6th wk to 2.3 U/ L values, but still 1.7x relative to CG values. However, there was no statistically significant difference in ALP and TRAP levels between the experimental and control groups. Plasma calcium levels in the EG increased through all the study periods, relative to decreasing Ca ion renal excretion. Data subjected to statistical analysis showed a significant difference between groups, in serum calcium levels at all periods (p = 0.01, 0.02, and 0.04, respectively) as well as in urine calcium at 6 wks (p = 0.04).
Soft X-ray in high-resolution films
Soft x-ray images from CZD, 1, 3, and 6 wks post-surgery, from groups treated and not treated with rhPTH, showed similar Figure 1 . rhPTH plasma levels (a) through one day after a single subcutaneous injection (mean values). rhPTH effect on bone metabolic markers. ALP (b) values showed a significant increase at the 1st, 3rd, and 6th wks with rhPTH treatment. TRAP (c) values showed a further decrease at the 1st wk, although there was an increase at the 3rd wk, and at the 6th wk, the values decreased again. There was no statistically significant difference between groups at both markers (p < 0.005, Mann-Whitney test). Serum calcium levels increased through all study periods, and renal excretion decreased relative to urine calcium (d). Data subjected to statistical analysis showed differences from serum calcium levels at all study periods (p = 0.01, 0.02, and 0.04, respectively), as well as urine calcium at 6 wks (p = 0.04), indicated by * (p < 0.05, Mann-Whitney test). 
Results
Concentrations of serum rhPTH
Serum levels of rhPTH increased immediately after a single subcutaneous injection, and maximum value was higher than 207.9 pg/mL at 10 min, decreasing to 89.2 pg/mL at 1 hr, and to 18.8 pg/ mL at 24 hrs (Fig. 1A) . results: rounded radiolucent areas on parietal bone, representing CZD healing by fibrous connective tissue. There were some internal radiopacities, which increased in size and numbers throughout the study, especially in the EG (Figs. 2A, 2B ).
Histopathology and histometric observations
In the control group, at the 1st wk post-surgery, the defect area exhibited granulation tissue and congestion in the superior sagittal sinus. At the 3rd and 6th wks, the CZD area showed fibrous connective tissue healing. In all 3 periods, there was almost no regenerated bone in the defects except in the immediate vicinity of the surgical margins (Fig. 3A) . In the experimental group, at the 1st wk, the CZD area showed granulation tissue and congestion of the superior sagittal sinus, as in the CG (Fig. 3B) . At the edges, the bone formed showed swirling cemental basophilic lines resembling disrupted mineralization (Fig. 3C) . Osteosclerosis was observed with cortical bone apposition on existing surfaces. Focal osteoblast hyperplasia was found on parietal bone surfaces, showing many active osteoblasts without connections to osteoclasts. Limited focal proliferation of spindleshaped stromal cell areas with fibrous connective tissue and vessels was observed (Fig. 4A) . Within the critical-sized defect area, rare woven bone islands were detected, covered with many lining cells surrounded by fibrous connective tissue with stromal cells, socalled 'fibrous osteodystrophy' (Fig. 3D) . At the 3rd and 6th wks, there was a significant increase (p=0.01 and 0.02, respectively) in bone thickness, and many sutures were healed.
Disrupted mineralization was also observed (Fig. 4B ). Periosteal and endosteal bone formation organized in a looping or networking pattern was diagnosed as hyperostosis (Fig. 4C) . Osteocytes from new bone or pre-existing bone were prominent, granular, and eosinophilic, showing intracellular hyaline body formation (IHB) and cell death (Fig. 4D) .
The Table shows the results of histometric analysis. The new bone formed in the EG at 1 wk (0.20% ± 0.02) and 3 wks (0.65% ± 0.02), compared with that formed in the CG (0.14% ± 0.1 and 0.40% ± 0.2, respectively), showed no significant statistical differences. At 6 wks, the EG showed significant bone formed (2.81% ± 0.6) compared with the CG (1.06% ± 0.2) (p = 0.023). 
Discussion
Clinical and experimental evidence supports the use of recombinant human parathyroid hormone for severe osteoporosis treatment, based on anabolic success with daily administration. This led us to believe that rhPTH may also have an anabolic effect in other bone loss lesions. The potential of systemic intermittent rhPTH administration to promote bone regeneration in large defects is unknown.
We selected a well-established critical-size defect model 11, 12) using rat calvaria bone, because its biological properties are similar to those of the human maxilla. Both are flat bones, with intramembranous ossification and two hard outer layer of cortical bone containing bone marrow. Further, CZD were selected because they are unable to undergo spontaneous bone regeneration. The results in a CZD rat model were obtained with a 20 g/kg/ day intermittent subcutaneous dose from 1 to 6 wks. We followed the regeneration process up to the sixth week to restrict the study to the maturity period of the animal, avoiding the old age phase during which the biological response is reduced. The doses were selected based on previous studies 15, 18) where rhPTH 5-30 g/kg/ day stimulated bone formation without side-effects. In our results, bone volume at edges and center of CZD in the EG was limited to 2.81± 0.6% at the 6th wk, while the value from the CG was 1.06 ± 0.2%. Because bone formation was observed on defect perimeters, CZD regeneration did not occur. However, pre-existing bone thickness increased in all study periods, and was statistically significant at 3 (p = 0.01) and 6 (p = 0.02) wks. From these results, it is reasonable to consider that the slight bone formation around the CZD was based on the short rhPTH half-life 7) , enough to trigger pre-existing bone multicellular units 19) , but insufficient to activate ¨determined osteoblasts¨ available in the dura mater 20, 21) . Rather than fully filling the bone defect, rhPTH generated few woven bone ossicles, surrounded by fusocellular lining cells in fibrous connective tissue that resembled fibrous osteodystrophy. Bone non-neoplastic proliferative lesions, like the focal osteoblast hyperplasia and focal stromal hyperplasia found in this research, have been previously described 15, 18, 22) , but with high doses of rhPTH (30, 50, and 75 g/kg/day). This is the first report on the use of rhPTH (20 g/kg/day) for systemic treatment alone for CZD rats without any osteoconductive matrices, that formed a small amount of inductive new bone. The results of the present study seem to be in disagreement with those from the study of CZD animal models where PTH and some biomaterials were used 13, 14) . In those studies, a significant amount of bone was formed, based on the osteoconductive ability of various bone replacements acting like a scaffold, and on the differences between whole PTH and recombinant hPTH biological action showed some degree of autophagic cell death, shown by Sudan black staining. We considered that rhPTH produced stress toxicity on bone cells, forming from IHB to cell death 24) . This could explain why many osteocytes apparently experienced an autophagic, caspase-independent, "type II" cell death, as observed by immunohistochemistry, and also possibly explained the increase in bone mass. In conclusion, systemic administration of rhPTH 25) , and may determine bone non-neoplastic proliferative lesions with disrupted mineralization.
